Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Xiaogang Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8173-5118; OpenAlex author ID A5082505204. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 7

  1. The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability. Last author DOI 10.1038/s41419-025-08001-4↗
  2. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA. Co-author DOI 10.1038/s41419-024-06729-z↗
  3. Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment. Co-author DOI 10.1038/s41419-024-07048-z↗
  4. TRIM16 promotes aerobic glycolysis and pancreatic cancer metastasis by modulating the NIK-SIX1 axis in a ligase-independent manner. Co-author PMID 36504902↗
  5. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα. Last author DOI 10.1038/s41388-020-01527-1↗
  6. USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1. Last author DOI 10.1038/s41419-021-04163-z↗
  7. RING-finger protein 6 enhances c-Myc-mediated Warburg effect by promoting MAD1 degradation to facilitate pancreatic cancer metastasis. Last author PMID 34094667↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Leifeng Chen · 6 shared papers, 2021–2025 · strength 1.04
  2. Yunyan Du · 4 shared papers, 2021–2024 · strength 0.71
  3. Wenming Zhang · 2 shared papers, 2024–2025 · strength 0.47
  4. Hengqing Zhu · 2 shared papers, 2021–2022 · strength 0.28
  5. Yumin Qiu · 2 shared papers, 2021–2022 · strength 0.28
  6. Rongfa Yuan · 2 shared papers, 2021 · strength 0.28
  7. Fan Zhou · 1 shared paper, 2024 · strength 0.22
  8. Li‐Ping Jiang · 1 shared paper, 2024 · strength 0.22
  9. Ying Huang · 1 shared paper, 2022 · strength 0.15
  10. Bin Zhou · 1 shared paper, 2022 · strength 0.15
  11. Xueqiang Deng · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.